antibody drug conjugate

SHANGHAI & CAMBRIDGE, Mass., Aug. 3, 2026 Zai Lab Limited announced that the U.S. Food and Drug Administration (FDA)...

SINGAPORE and NORTH BRUNSWICK, N.J., Aug. 3, 2026 Adlai Nortye Ltd. has advanced its oncology pipeline after submitting a...

SHANGHAI, China, July 27, 2026 IMPACT Therapeutics announced the nomination of IMP3201 as a preclinical candidate (PCC), marking the...

TOKYO, July 31, 2026 Daiichi Sankyo and AstraZeneca announced that the European Commission (EC) has approved Datroway® (datopotamab deruxtecan)...

NORWOOD, Mass., July 28, 2026 Corbus Pharmaceuticals Holdings, Inc. has received U.S. Food and Drug Administration (FDA) clearance to...

Newcastle, UK, July 30, 2026 Iksuda Therapeutics has received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)...

Hong Kong, July 27, 2026 Akeso, Inc. has announced that the first patient has been dosed in the Phase...

CAMBRIDGE, UK, July 27, 2026 AstraZeneca has announced positive high-level results from the global Phase III CLARITY-Gastric01 trial, demonstrating...

Zurich, Switzerland, July 27, 2026 VERAXA Biotech AG announced the advancement of its VXA-222 bispecific antibody-drug conjugate (bsADC) program...

Tokyo, July 24, 2026 Daiichi Sankyo and AstraZeneca announced that the European Medicines Agency’s Committee for Medicinal Products for...